Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Rotavirus is the commonest cause of severe gastroenteritis in young children worldwide. The investigators hypothesize that use of a food based prophylactic will decrease incidence of rotavirus infection in young children in south India, prevent intestinal damage and overall result in lower infection rates and better gut function. This trial will evaluate the efficacy of prevention of rotavirus gastroenteritis when an anti-rotavirus protein or antibody fragments expressed in yeast or placebo are given daily as a food supplement to children between the ages of 6 and 12 months. The children will followed for one year and rates of rotavirus diarrhoea, antibody responses and gut function will be compared between children receiving antibody fragments or placebo.
| Condition | Intervention | Phase |
|---|---|---|
|
Rotavirus Gastroenteritis |
Dietary Supplement: Anti-rotavirus protein Dietary Supplement: Maltodextrin |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Community Based Prophylaxis for Rotavirus Gastroenteritis in Children by an Anti-rotavirus Protein Based Food Supplement |
- Incidence of rotavirus gastroenteritis [ Time Frame: One year after recruitment ] [ Designated as safety issue: No ]
- IgA And IgG Antibody Response To Rotavirus [ Time Frame: At 4, 8 And 12 Months after recruitment ] [ Designated as safety issue: No ]
- Weight For Height Z Score [ Time Frame: At 6 and 12 months after recruitment ] [ Designated as safety issue: No ]
- Intestinal Function by lactulose:mannitol [ Time Frame: at 3, 6, 9 and 12 months ] [ Designated as safety issue: No ]
- Characterization of strains causing rotavirus gastroenteritis [ Time Frame: Over 12 months ] [ Designated as safety issue: No ]
- Incidence of adverse events [ Time Frame: Over 12 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 300 |
| Study Start Date: | December 2010 |
| Estimated Study Completion Date: | July 2012 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Anti-rotavirus protein |
Dietary Supplement: Anti-rotavirus protein
11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
|
| Placebo Comparator: Maltodextrin |
Dietary Supplement: Maltodextrin
Maltodextrin 1 gm daily
|
Detailed Description:
The study will be carried out in an urban slum area in Vellore, south India. Children between the ages of 6 and 12 months will be recruited for participation in the study. They will be randomized to receive supplementation with ARP or placebo, and will be followed for a period of one year, with weekly home visits and monitoring of all episodes of diarrhoea. In addition, every two weeks, surveillance stool samples will be collected and tested for rotavirus to identify asymptomatic infections by PCR. All episodes of diarrhoea will be investigated intensively for bacterial, viral and parasitic agents of diarrhoea using both conventional and molecular techniques and all cases will be treated appropriately at the study clinic or referral hospital as required. Monthly anthropometric measurements will be carried out to estimate rates of growth and to identify growth faltering. Blood samples will be taken at 4, 8 and 12 months for estimation of anti-rotavirus IgA and IgG antibodies. Studies on intestinal absorption and permeability will be carried out at recruitment, 6 and 12 months by the lactulose:mannitol test (measured by HPLC detection of sugars). All rotavirus strains obtained will be characterized by genotyping.
Eligibility| Ages Eligible for Study: | 6 Months to 12 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy child aged 6 to 12 months, families resident in the study area, willing to participate and available for follow up for a period of one year
- Normal birth weight (> 2.5 kg), child exclusively breast fed for at least four months
Exclusion Criteria:
- Families not available for a follow up period of one year
- Children with any atopic conditions
- Children with gross congenital anomalies including cardiovascular, renal or hepatic disease
- Children with syndromic or serological evidence of HIV infection
Contacts and Locations| Contact: Gagandeep Kang, MD, PhD | +914162282052 | gkang@cmcvellore.ac.in |
| Contact: George Mathew, MS | +914162284202 | princi@cmcvellore.ac.in |
| India | |
| Christian Medical College | Not yet recruiting |
| Vellore, TN, India, 632004 | |
| Contact: Gagandeep Kang, MD, PhD +914162282052 gkang@cmcvellore.ac.in | |
| Principal Investigator: Gagandeep Kang, MD, PhD | |
| Sub-Investigator: Jayaprakash Muliyil, MD, DrPH | |
| Sub-Investigator: Anuradha Bose, MD,FRCPCH | |
More Information
No publications provided
| Responsible Party: | Principal, Christian Medical College, Vellore |
| ClinicalTrials.gov Identifier: | NCT01265355 History of Changes |
| Other Study ID Numbers: | CMCLB001 |
| Study First Received: | December 21, 2010 |
| Last Updated: | December 22, 2010 |
| Health Authority: | India: Indian Council of Medical Research India: Institutional Review Board |
Additional relevant MeSH terms:
|
Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013